KEY FEATURES
| Full Name | Tumor Necrosis Factor Ligand Superfamily, Member 13 |
|---|---|
| Synonym | CD256; APRIL; TALL2; TRDL1; ZTNF2; A Proliferation Inducing Ligand; TNF And APOL Related Leukocyte Expressed Ligand 2; TNF-Related Death Ligand 1 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 46.88-3000pg/mL |
| Sensitivity | 17.74pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human TNFSF13 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human TNFSF13. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human TNFSF13 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human TNFSF13, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human TNFSF13. You can calculate the concentration of Human TNFSF13 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES
TYPICAL DATA
Human TNFSF13 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 150.99 | 271.43 | 1412.24 | 142.15 | 263.07 | 1527.21 |
| Standard deviation | 9.35 | 15.12 | 65.25 | 8.33 | 11.94 | 50.4 |
| CV(%) | 6.19 | 5.57 | 4.62 | 5.86 | 4.54 | 3.3 |
RECOVERY
The recovery of Human TNFSF13 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 84-99 | 91 |
| EDTA plasma (n=8) | 95-112 | 102 |
| Cell culture media (n=8) | 92-104 | 99 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human TNFSF13 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.
Products associated with TNFSF13 ELISA Kits
| TNFSF13B ELISA Kit | publications with TNFSF13 and TNFSF13B |
| TNFRSF17 ELISA Kit | publications with TNFSF13 and TNFRSF17 |
| TNFRSF13B ELISA Kit | publications with TNFSF13 and TNFRSF13B |
| SET ELISA Kit | publications with TNFSF13 and SET |
| FURIN ELISA Kit | publications with TNFSF13 and FURIN |
Pathways associated with TNFSF13 ELISA Kit
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| Gene Expression Pathway | Gene Expression Pathway |
| HuR Stabilizes MRNA Pathway | HuR Stabilizes MRNA Pathway |
| Intestinal Immune Network For IgA Production Pathway | Intestinal Immune Network For IgA Production Pathway |
| Regulation Of MRNA Stability By Proteins That Bind AU-rich Elements Pathway | Regulation Of MRNA Stability By Proteins That Bind AU-rich Elements Pathway |
| Rheumatoid Arthritis Pathway | Rheumatoid Arthritis Pathway |
| Spinal Cord Injury Pathway | Spinal Cord Injury Pathway |
Diseases associated with TNFSF13 ELISA Kit
| Necrosis | publications with TNFSF13 and Necrosis |
| Inflammation | publications with TNFSF13 and Inflammation |
| Disease Models, Animal | publications with TNFSF13 and Disease Models, Animal |
| Cardiovascular Diseases | publications with TNFSF13 and Cardiovascular Diseases |
| Colorectal Neoplasms | publications with TNFSF13 and Colorectal Neoplasms |
| Nervous System Diseases | publications with TNFSF13 and Nervous System Diseases |
| Kidney Diseases | publications with TNFSF13 and Kidney Diseases |
| Liver Neoplasms | publications with TNFSF13 and Liver Neoplasms |
| Neoplasms, Experimental | publications with TNFSF13 and Neoplasms, Experimental |
| Liver Diseases | publications with TNFSF13 and Liver Diseases |
Organs/Tissues associated with TNFSF13 ELISA Kit
| Blood | publications with TNFSF13 and Blood |
| Bone | publications with TNFSF13 and Bone |
| Spleen | publications with TNFSF13 and Spleen |
| Lung | publications with TNFSF13 and Lung |
| Kidney | publications with TNFSF13 and Kidney |
| Lymph Node | publications with TNFSF13 and Lymph Node |
| Skin | publications with TNFSF13 and Skin |
| Liver | publications with TNFSF13 and Liver |
| Vascular | publications with TNFSF13 and Vascular |
| Mouth | publications with TNFSF13 and Mouth |
